Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
Total Valuation
Inovio Pharmaceuticals has a market cap or net worth of $77.75M. The enterprise value is -$28.57B.
Market Cap$77.75M
Enterprise Value-$28.57B
Share Statistics
Inovio Pharmaceuticals has 36,674,435 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding36,674,435
Owned by Insiders0.73%
Owned by Institutions10.93%
Financial Efficiency
Inovio Pharmaceuticals’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.14%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)-0.95
Return on Invested Capital (ROIC)-0.14%
Return on Capital Employed (ROCE)-1.44
Revenue Per Employee1.63K
Profits Per Employee-800.40K
Employee Count134
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inovio Pharmaceuticals is -0.46. Inovio Pharmaceuticals’s PEG ratio is -0.02.
PE Ratio-0.46
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio-0.02
Income Statement
In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K and earned -107.25M in profits. Earnings per share was -3.95.
Revenue217.76K
Gross Profit-2.91M
Operating Income-112.40M
Pretax Income-107.25B
Net Income-107.25M
EBITDA-103.95M
Earnings Per Share (EPS)-3.95
Cash Flow
In the last 12 months, operating cash flow was -111.28B and capital expenditures 35.58K, giving a free cash flow of -111.28B billion.
Operating Cash Flow-111.28B
Free Cash Flow-111.28B
Free Cash Flow per Share-3.03K
Dividends & Yields
Inovio Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.69
52-Week Price Change-78.34%
50-Day Moving Average1.84
200-Day Moving Average3.48
Relative Strength Index (RSI)61.57
Average Volume (3m)517.18K
Important Dates
Inovio Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Inovio Pharmaceuticals as a current ratio of 2.77, with Debt / Equity ratio of 21.99%
Current Ratio2.77
Quick Ratio2.77
Debt to Market Cap0.00
Net Debt to EBITDA519.00
Interest Coverage Ratio-632.05
Taxes
In the past 12 months, Inovio Pharmaceuticals has paid -107.15B in taxes.
Income Tax-107.15B
Effective Tax Rate1.00
Enterprise Valuation
Inovio Pharmaceuticals EV to EBITDA ratio is 518.52, with an EV/FCF ratio of 515.46.
EV to Sales-247.52K
EV to EBITDA518.52
EV to Free Cash Flow515.46
EV to Operating Cash Flow517.87
Balance Sheet
Inovio Pharmaceuticals has $68.36B in cash and marketable securities with $11.27B in debt, giving a net cash position of -$57.09B billion.
Cash & Marketable Securities$68.36B
Total Debt$11.27B
Net Cash-$57.09B
Net Cash Per Share-$1.56K
Tangible Book Value Per Share$2.52
Margins
Gross margin is -636.81%, with operating margin of -51616.91%, and net profit margin of -49254.27%.
Gross Margin-636.81%
Operating Margin-51616.91%
Pretax Margin-49254269.00%
Net Profit Margin-49254.27%
EBITDA Margin-47735.19%
EBIT Margin-49172.60%
Analyst Forecast
The average price target for Inovio Pharmaceuticals is $8.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.25
Price Target Upside280.18% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast-60.52%
EPS Growth Forecast42.41%